A prognosis for GE and Abbott Diagnostics
...lar marketing capabilities apply. Convergence of biologics and radiology In the fall of 2004, GE completed an 8.1 billion acquisition of United Kingdom-based healthcare company Amersham . Its medical diagnostics unit is a leader in developing and producing contrast agents for use in diagnostic imaging. W...FDA programs encourage and expedite drug development and approval
...reated incentives for the development of drugs and biologics for rare diseases. Last month, the Wall Street Jou...differently than the larger population. Drugs and biologics designated as orphan products are eligible for four major economic incentives: Grants for clinical...Animal testing: Beyond the protests, instances of mistreatment are rare
...ed to 111 USDA-approved biotech-derived veterinary biologics and vaccines that improve the health of livestock, poultry and companion animals. Biotech veterinary products to treat heartworm, arthritis, parasites, allergies and heart disease, as well as vaccines for rabies and feline HIV, are used daily by vete...Fast Track: FDA User Fees: Do Faster Review Times Justify the Financial Burden?
...d the fees associated with new medical devices and biologics can exceed $150,000. The strain on smaller businesses is significant, and an unintended consequence of user fees may be to weaken innovative start-up companies. Moreover, user fees have created a two-tiered review system, where FDA reviews fee-based ...Biologicals Transfer Proposal between US and Indian Biotechnology
...ion led by science minister Kapil Sibal led to the biologics transfer proposal. Under the plan, India’s Department of Biotechnology (DBT) would procure biological material from the American Type Tissue Collection (ATCC) and warrant against their misuse or subsequent acquisition by bioterrorists, with safeguard...Biocon To Shift Focus On Innovation To Accelerate Growth
...ons. With the commissioning of the multi-product biologics facility (Biopharmaceuticals) this month in its Biotech Park, the company is gearing up to manufacture a range of monoclonal anti-bodies and other recombinant therapeutic products. "We have completed registration enabling clinical trials for our th...Ranbaxy Signs Agreement With Zenotech For Cancer Drugs
...t facilities in India and the US. Its oncology and biologics manufacturing facilities are located in India. 'This strategic initiative by RPI will establish our presence in the therapeutic arena by offering a basket of products in the US and Canadian markets that has breadth and depth in the management of pat...International Collaboration Takes Aim at Rabies
...ic mission is to bring cost-effective vaccines and biologics to the developing world. Today, half of all childr...ction facility, thereby bringing this leading-edge biologics technology to India for the first time. Serum Institute already produces much of the rabies vaccine ......opines that rival products also known as follow-on biologics should be put up for extensive clinic studies and ...’s legislation on biosimilars, told the panel some biologics like insulin and human growth hormones are fairly simple to produce as generics, but that other more...Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease
...l developmentspecialist that in-licenses promising biologics and small moleculedrug candidates. Debiopharm develops its products for globalregistration and maximum commercial potential for out-licensing topharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development...Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
...ionalcombinations of ERBITUX with chemotherapy and biologics in patientswith this aggressive cancer for whom treatment options remainacutely limited. Other ERBITUX data presented at ASCO included the following: -- Two randomized studies evaluated ERBITUX combined withoxaliplatin-based chemotherapy in first l...Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal
... and enhance the retention of anti-cancerdrugs and biologics within tumours. The drug becomes entrainedwithin the HA matrix and the HA binds to receptors located on thetumour cell resulting in more of the drug being delivered to thetumour. Preclinically, the HyACT(TM) technology has demonstratedimproved delive...